James J. Rusthoven - Concepedia

Author

James J. Rusthoven

Also Known As

J J Rusthoven, J RUSTHOVEN, J Rusthoven, J. J. Rusthoven, J. Rusthoven, J.J Rusthoven, J.J. Rusthoven, JAMES J. RUSTHOVEN, JAMES RUSTHOVEN, James J Rusthoven

Publications

Citations

H-Index

Concepts

All Affiliations

Ontario Institute for Cancer Research Eli Lilly (United States)McMaster University Princess Margaret Cancer Centre Hamilton Regional Laboratory Medicine Program

About

James J. Rusthoven is an author at Ontario Institute for Cancer Research specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	23	1.1K
2	Health Sciences	5	5	157
3	Cell Biology	3	3	88
4	Public Health	2	2	46
5	Anesthesia	1	1	28

James J. Rusthoven

Publications

5.6K

Citations

H-Index

Page 1

	Year	Citations
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma Nicholas J. Vogelzang, James J. Rusthoven, James T. Symanowski, Journal of Clinical Oncology	2003	3K
Phase II Study of Pemetrexed With and Without Folic Acid and Vitamin B<sub>12</sub> as Front-Line Therapy in Malignant Pleural Mesothelioma Giorgio V. Scagliotti, Dong-M. Shin, Hedy L. Kindler, Journal of Clinical Oncology	2003	255
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma Nicholas J. Vogelzang, James J. Rusthoven, James T. Symanowski, Journal of Clinical Oncology	2023	251
Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Clet Niyikiza, Sharyn D. Baker, David E. Seitz, PubMed Drug SafetyPretreatment Methylmalonic AcidTherapeutic Drug MonitoringOncologyPemetrexed Therapy	2002	247
Multitargeted Antifolate LY231514 as First-Line Chemotherapy for Patients With Advanced Non–Small-Cell Lung Cancer: A Phase II Study James J. Rusthoven, Elizabeth A. Eisenhauer, Charles Butts, Journal of Clinical Oncology	1999	218
Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group. James J. Rusthoven, Ian Quirt, N. Iscoe, Journal of Clinical Oncology	1996	167
Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma Frances A. Shepherd, Janet Dancey, Andrew Arnold, Cancer	2001	145
Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group. Jean Latreille, Joseph L. Pater, D. Johnston, Journal of Clinical Oncology	1998	117
Varicella-Zoster Infection in Adult Cancer Patients James J. Rusthoven Archives of Internal Medicine OncologyCervical CancerVaricella-zoster InfectionPathogenesisHealthcare-associated Infection	1988	115
Impact of chemotherapy-associated nausea and vomiting on patients' functional status and on costs: survey of five Canadian centres. B O’Brien, James J. Rusthoven, A. Rocchi, PubMed	1993	90

Page 1